At DOC 2024, the Director of the UCSF Breast Cancer Center lays down the WISDOM on early detection and treatment.
(This article was created in collaboration with Claude AI)
Key Takeaways:
- The Surgeon Who Puts Surgery Second. Dr. Laura Esserman, Director of the UCSF Breast Cancer Center, believes the greatest leap in cancer care comes from flipping the script — starting with systemic therapy to understand tumor biology before cutting, rather than surgery first, questions later.
- Your Family Tree Might Be Lying to You. Esserman’s ongoing WISDOM study revealed 65% of people with cancer-related genetic mutations had no family history, shattering assumptions about who needs genetic testing and paving the way for risk-based screening, starting first with risk assessment, including genetic testing.
- Not All Cancer Needs Aggressive Treatment. Up to 60% of DCIS cases may not require invasive interventions. Her RECAST trial challenges the surgery-first mentality for ductal carcinoma in situ, exploring whether surveillance can be as or more effective as aggressive treatment.
- Speed Matters — But So Does Precision. Her I-SPY TRIALS match therapies to tumor biology in real-time, with MRI scans revealing response patterns that let doctors pivot quickly when treatments aren’t working, and to stop early when they are (e.g. when the tumor is gone.)
- Courage Over Convention. Esserman builds clinical trials around calculated risks that challenge decades of “how we’ve always done it.”
At DOC 2024‘s “Smarter Than Cancer” session in Napa Valley, breast surgeon and breast oncology specialist Dr. Laura Esserman posed a radical question: What if we’ve been doing cancer treatment backwards?
“Those three words, ‘You have cancer,’ strike fear into a woman’s heart,” Esserman said. “So, what do we do to change that?”
As Director of the UCSF Breast Cancer Center, Esserman has spent her career questioning medicine’s sacred cows. Traditional oncology follows a predictable playbook: diagnosis, surgery, then standardized treatment. Esserman flips that script. For high-risk cancers, she starts with systemic therapy, watching how tumors respond before making the next move.
“Let’s figure out what kind of biology you have, start testing the new drugs, and start figuring out how to improve them,” she explained. “If you respond, great… And if you don’t, we are forearmed and can try the next best treatement.”
Her I-SPY TRIALS have produced remarkable results: the most recent results using a new type of treatment — an antibody linked to a toxin to target tumors — showed that 55% of people with a specific immune subtype achieved complete response — no detectable cancer — without standard chemotherapy. Ninety percent avoided AC, an intensive chemo treatment that has long been a cornerstone of breast cancer care.
Esserman’s revolution extends beyond treatment into screening. Her WISDOM study with 45,000 participants (now 75,000 including WISDOM 2.0) shattered assumptions about genetic risk: 65% of those with cancer-related mutations had no family history — challenging everything we thought we knew about who needs genetic testing. When 75% of biopsies that are generated from screening yield benign results, she believes genetic profiling, in addition to other risk factors, should guide decisions about screening and prevention, not fear.”
Perhaps most provocatively, Esserman targets ductal carcinoma in situ (DCIS), abnormal cells that may develop into invasive cancer. Found routinely through mammograms, DCIS traditionally triggers immediate intervention. But Esserman suggests up to 60% of cases may not need aggressive treatment.
That prompted her to launch the RECAST DCIS trial, a national platform to test whether surveillance can match or outperform surgery’s effectiveness.
“Patients want something better, more effective, and less toxic, and we have to aspire to do better,” Esserman said. “I am very proud of building a culture around all of these trials that allows us to take the risks that we need to make the future better for all who are being screened or treated for breast cancer.”
Those risks are calculated ones, driven by a simple recognition: behind every trial is a person who deserves better than fear.